Published in J Virol on June 01, 1990
Clonal analysis of a human antibody response. II. Sequences of the VH genes of human IgM, IgG, and IgA to rabies virus reveal preferential utilization of VHIII segments and somatic hypermutation. J Immunol (1993) 1.65
Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A (1992) 1.60
Antigenicity of rabies virus glycoprotein. J Virol (1991) 1.50
Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol (2005) 1.22
Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis (2009) 1.21
Rabies virus (RV) glycoprotein expression levels are not critical for pathogenicity of RV. J Virol (2010) 1.18
Function and glycosylation of plant-derived antiviral monoclonal antibody. Proc Natl Acad Sci U S A (2003) 1.16
Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum (2000) 1.05
Novel rabies virus-neutralizing epitope recognized by human monoclonal antibody: fine mapping and escape mutant analysis. J Virol (2005) 1.00
Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells. Proc Natl Acad Sci U S A (2006) 0.92
Novel approaches and challenges to treatment of central nervous system viral infections. Ann Neurol (2013) 0.90
A recombinant human Fab expressed in Escherichia coli neutralizes rabies virus. J Virol (1992) 0.88
Rabies virus neuritic paralysis: immunopathogenesis of nonfatal paralytic rabies. J Virol (1992) 0.83
Phage display-derived human antibodies in clinical development and therapy. MAbs (2016) 0.79
Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. J Infect Dis (2014) 0.78
Molecular docking studies with rabies virus glycoprotein to design viral therapeutics. Indian J Pharm Sci (2010) 0.77
Use of hyperimmune anti-rabies serum concentrates in experimental rabies. Am J Med (1950) 5.68
Structural basis of antibody function. Annu Rev Immunol (1983) 3.41
Antigenic variants of rabies virus. J Exp Med (1980) 2.51
Rabies group-specific ribonucleoprotein antigen and a test system for grouping and typing of rhabdoviruses. J Virol (1973) 2.40
Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand (1984) 2.20
Induction and biological properties of defective interfering particles of rabies virus. J Virol (1977) 2.02
Effective protection of monkeys against death from street virus by post-exposure administration of tissue-culture rabies vaccine. Bull World Health Organ (1971) 1.85
Studies on chick-embryo-adapted rabies virus. IV. Immunization of guinea-pigs and description of a potency control test. J Immunol (1954) 1.60
Localization and immunological characterization of antigenic domains of the rabies virus internal N and NS proteins. Virus Res (1987) 1.42
Clonal analysis of a human antibody response. Quantitation of precursors of antibody-producing cells and generation and characterization of monoclonal IgM, IgG, and IgA to rabies virus. J Exp Med (1990) 1.38
Isolation and purification of a polymeric form of the glycoprotein of rabies virus. J Gen Virol (1978) 1.26
Characterization of a new virus-neutralizing epitope that denotes a sequential determinant on the rabies virus glycoprotein. J Gen Virol (1989) 1.15
Investigation of the antigenic structure of rabies virus glycoprotein by monoclonal antibodies. Dev Biol Stand (1984) 1.08
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care (1997) 8.52
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Activation of production of infectious tumor virus SV40 in heterokaryon cultures. Proc Natl Acad Sci U S A (1967) 6.05
Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med (1979) 5.58
Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol (2005) 5.27
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93
Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc Natl Acad Sci U S A (1983) 4.54
Chromosomal location of the genes for human immunoglobulin heavy chains. Proc Natl Acad Sci U S A (1979) 4.52
Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin Infect Dis (2013) 4.51
Effect of virus infections on the function of the immune system. Annu Rev Microbiol (1970) 4.30
Production of antibodies against influenza virus by somatic cell hybrids between mouse myeloma and primed spleen cells. Proc Natl Acad Sci U S A (1977) 4.30
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell (1995) 4.13
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature (1985) 3.62
Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med (1979) 3.62
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol (1997) 3.61
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature (1984) 3.32
Solid-phase enzyme immunoassay or radioimmunoassay for the detection of immune complexes based on their recognition by conglutinin: conglutinin-binding test. A comparative study with 125I-labelled Clq binding and Raji-cell RIA tests. Clin Exp Immunol (1977) 3.27
Comparison of the ribonucleic acid polymerases of two rhabdoviruses, Kern Canyon virus and vesicular stomatitis virus. J Virol (1971) 3.26
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res (1983) 3.15
Monoclonal antibodies against rabies virus produced by somatic cell hybridization: detection of antigenic variants. Proc Natl Acad Sci U S A (1978) 3.03
CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. Immunol Today (1989) 2.96
Thymus dependence of viral antigens. Nature (1975) 2.95
Heterogeneity in the properties of 7 S and 19S rabbit-neutralizing antibodies to herpes simplex virus. J Immunol (1968) 2.90
Tyro-3 family receptors are essential regulators of mammalian spermatogenesis. Nature (1999) 2.80
Continued expression of a poly(A)+ transcript of herpes simplex virus type 1 in trigeminal ganglia of latently infected mice. J Virol (1987) 2.78
Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science (1987) 2.75
Latent ganglionic infection with herpes simplex virus types 1 and 2: viral reactivation in vivo after neurectomy. Science (1974) 2.71
The CDR1 sequences of a major proportion of human germline Ig VH genes are inherently susceptible to amino acid replacement. Immunol Today (1994) 2.71
Antigenic properties of rabies virus components. J Immunol (1973) 2.68
Infectious virus-antibody complex in the blood of chronically infected mice. J Exp Med (1966) 2.68
Purification of rabies virus grown in tissue culture. J Virol (1968) 2.67
Effect of polyions on the infectivity of rabies virus in tissue culture: construction of a single-cycle growth curve. J Virol (1967) 2.67
New assay procedure for separation of mycoplasmas from virus pools and tissue culture systems. J Virol (1967) 2.64
Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. Annu Rev Immunol (1989) 2.63
Assignment of the T-antigen gene of simian virus 40 to human chromosome C-7. Proc Natl Acad Sci U S A (1973) 2.63
Detection of serum antibodies to Borna disease virus in patients with psychiatric disorders. Science (1985) 2.57
Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings. N Engl J Med (1978) 2.55
Antigenic variants of rabies virus. J Exp Med (1980) 2.51
Unexplained rabies in three immigrants in the United States. A virologic investigation. N Engl J Med (1991) 2.50
Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci U S A (1992) 2.48
Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA (1976) 2.47
Human CD4+ cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat Med (1997) 2.47
Herpes simplex type 1 DNA in human brain tissue. Proc Natl Acad Sci U S A (1981) 2.45
Inhibition or enhancement of immunological injury of virus-infected cells. Proc Natl Acad Sci U S A (1971) 2.45
Analysis of the structural correlates for antibody polyreactivity by multiple reassortments of chimeric human immunoglobulin heavy and light chain V segments. J Exp Med (1994) 2.44
Structural proteins of rabies virus. J Virol (1971) 2.42
Prevention of cell-to-cell spread of herpes simplex virus by leukocytes. J Exp Med (1973) 2.42
Effect of environmental pH on the efficiency of cellular hybridization. Proc Natl Acad Sci U S A (1972) 2.39
Repertoire of antiviral antibodies expressed by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 2.38
Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice. Science (1985) 2.34
Production of human hybridomas secreting antibodies to measles virus. Nature (1980) 2.32
In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus. Proc Natl Acad Sci U S A (1972) 2.29
Immune lysis of rabies virus-infected cells. J Immunol (1968) 2.25
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
Influenza virus hemagglutinin-specific antibodies isolated from a combinatorial expression library are closely related to the immune response of the donor. Proc Natl Acad Sci U S A (1990) 2.24
Amplification and molecular cloning of HTLV-I sequences from DNA of multiple sclerosis patients. Science (1989) 2.23
Immune mechanisms by which the spread of viral infections is stopped. Cell Immunol (1974) 2.23
Comparison of direct and indirect solid-phase microradioimmunoassays for the detection of viral antigens and antiviral antibody. Appl Microbiol (1973) 2.23
Molecular recognition and the future of monoclonal antibodies. Nature (1982) 2.22
Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A (1998) 2.21
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev Biol Stand (1984) 2.20
Presence of 2 different viral agents in brain cells of patients with subacute sclerosing panencephalitis. Proc Soc Exp Biol Med (1970) 2.20
Early events in the infection of permissive cells with simian virus 40: adsorption, penetration, and uncoating. J Virol (1970) 2.18
HIV-associated nephropathy in transgenic mice expressing HIV-1 genes. Virology (1991) 2.16
IgG2a monoclonal antibodies inhibit human tumor growth through interaction with effector cells. Proc Natl Acad Sci U S A (1982) 2.15
Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J Virol (1998) 2.15
Morphology of the nucleoprotein component of rabies virus. J Virol (1968) 2.13
Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. DNA Cell Biol (1994) 2.13
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Virus-induced diabetes mellitus. XVIII. Inhibition by a nondiabetogenic variant of encephalomyocarditis virus. J Exp Med (1980) 2.07
Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J Virol (1999) 2.04
Laboratory techniques in rabies. Mouse inoculation test. Monogr Ser World Health Organ (1966) 2.04
Induction and biological properties of defective interfering particles of rabies virus. J Virol (1977) 2.02
Virus particles in early mouse embryos. J Natl Cancer Inst (1973) 2.02
A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science (1981) 2.02
Epidemiologic characteristics of rabies virus variants in dogs and cats in the United States, 1999. J Am Vet Med Assoc (2001) 2.01
Differences in cell-to-cell spread of pathogenic and apathogenic rabies virus in vivo and in vitro. J Virol (1985) 2.00
Structure and development of rabies virus in tissue culture. J Virol (1967) 2.00
Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol (1978) 1.99
Herpes simplex virus DNA and mRNA sequences in acutely and chronically infected trigeminal ganglia of mice. Virology (1978) 1.99
Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc Soc Exp Biol Med (1969) 1.99
The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity (2001) 1.98
Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature (1985) 1.96
IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. Cancer Res (1993) 1.96
Use of hybridoma monoclonal antibodies in the detection of antigenic differences between rabies and rabies-related virus proteins. II. The glycoprotein. J Gen Virol (1980) 1.96
Latent infection of sensory ganglia with herpes simplex virus: efficacy of immunization. Science (1975) 1.95
Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc Natl Acad Sci U S A (1996) 1.95